Kala Bio Inc (KALA)
6.59
-0.14
(-2.08%)
USD |
NASDAQ |
May 17, 16:00
6.59
0.00 (0.00%)
After-Hours: 20:00
Kala Bio Enterprise Value: 1.743M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 1.743M |
| May 16, 2024 | 2.25M |
| May 15, 2024 | 2.324M |
| May 14, 2024 | 2.630M |
| May 13, 2024 | 2.493M |
| May 10, 2024 | 2.729M |
| May 09, 2024 | 2.202M |
| May 08, 2024 | 3.236M |
| May 07, 2024 | 2.785M |
| May 06, 2024 | 2.842M |
| May 03, 2024 | 3.031M |
| May 02, 2024 | 2.320M |
| May 01, 2024 | 2.475M |
| April 30, 2024 | 2.504M |
| April 29, 2024 | 2.588M |
| April 26, 2024 | 1.039M |
| April 25, 2024 | 0.701M |
| April 24, 2024 | 1.321M |
| April 23, 2024 | 1.788M |
| April 22, 2024 | 1.123M |
| April 19, 2024 | 1.856M |
| April 18, 2024 | 2.475M |
| April 17, 2024 | 2.554M |
| April 16, 2024 | 2.588M |
| April 15, 2024 | 3.010M |
| Date | Value |
|---|---|
| April 12, 2024 | 3.574M |
| April 11, 2024 | 3.574M |
| April 10, 2024 | 3.996M |
| April 09, 2024 | 4.165M |
| April 08, 2024 | 4.757M |
| April 05, 2024 | 4.700M |
| April 04, 2024 | 5.123M |
| April 03, 2024 | 5.207M |
| April 02, 2024 | 5.799M |
| April 01, 2024 | 5.799M |
| March 28, 2024 | 5.742M |
| March 27, 2024 | 4.956M |
| March 26, 2024 | 5.039M |
| March 25, 2024 | 5.122M |
| March 22, 2024 | 5.343M |
| March 21, 2024 | 5.370M |
| March 20, 2024 | 5.232M |
| March 19, 2024 | 4.598M |
| March 18, 2024 | 4.542M |
| March 15, 2024 | 4.073M |
| March 14, 2024 | 4.349M |
| March 13, 2024 | 4.404M |
| March 12, 2024 | 4.184M |
| March 11, 2024 | 4.874M |
| March 08, 2024 | 3.990M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-8.255M
Minimum
Mar 01 2023
643.29M
Maximum
Jun 02 2020
145.73M
Average
88.54M
Median
Enterprise Value Benchmarks
| CEL-SCI Corp | 63.47M |
| AIM ImmunoTech Inc | 7.729M |
| IGC Pharma Inc | 34.45M |
| NovaBay Pharmaceuticals Inc | 5.156M |
| Protalix BioTherapeutics Inc | 55.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.627M |
| Total Expenses (Quarterly) | 7.486M |
| EPS Diluted (Quarterly) | -3.18 |
| Earnings Yield | -273.9% |
| Normalized Earnings Yield | -996.49 |